HDAC6 and cancer: Interestingly, tubastatin A, a selective HDAC6 inhibitor, overcomes both ferroptosis resistance and radioresistance in cancer cells by inhibiting GPX4 enzymatic activity, independent of histone deacetylase 6 (HDAC6) inhibition[113].